Expenditure on the NHS during and after the Thatcher years: its growth and utilisation
Author
Abstract
Suggested Citation
Download full text from publisher
References listed on IDEAS
- Tony Scott & Alan Maynard, 1991. "Will the new GP contract lead to cost effective medical practice?," Working Papers 082chedp, Centre for Health Economics, University of York.
- DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G. & Lasagna, Louis, 1991. "Cost of innovation in the pharmaceutical industry," Journal of Health Economics, Elsevier, vol. 10(2), pages 107-142, July.
- Roy Carr-Hill & Paul Dixon & Ian Gibbs & Mary Griffiths & Moira Higgins & Dorothy McMaughan & Ken Wright, 1992. "Skill mix and the effectiveness of nursing care," Working Papers 015cheop, Centre for Health Economics, University of York.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Richardson, Gerald & Maynard, Alan & Cullum, Nicky & Kindig, David, 1998. "Skill mix changes: substitution or service development?," Health Policy, Elsevier, vol. 45(2), pages 119-132, August.
- Gerald Richardson & Alan Maynard, 1995. "Fewer doctors? More nurses? A review of the knowledge base of doctor-nurse substitution," Working Papers 135chedp, Centre for Health Economics, University of York.
- J Mohan, 1995. "Post-Fordism and Welfare: An Analysis of Change in the British Health Sector," Environment and Planning A, , vol. 27(10), pages 1555-1576, October.
- Street, Andrew & Duckett, Stephen, 1996. "Are waiting lists inevitable?," Health Policy, Elsevier, vol. 36(1), pages 1-15, April.
- Karen Bloor & Alan Maynard & Andrew Street, 1999. "The cornerstone of Labour's 'New NHS': reforming primary care," Working Papers 168chedp, Centre for Health Economics, University of York.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Alan Maynard & Arthur Walker, 1993. "Planning the medical workforce: struggling out of the time warp," Working Papers 105chedp, Centre for Health Economics, University of York.
- Karen Bloor & Alan Maynard, 1995. "Equity in primary care," Working Papers 141chedp, Centre for Health Economics, University of York.
- Scherer, F.M., 2010. "Pharmaceutical Innovation," Handbook of the Economics of Innovation, in: Bronwyn H. Hall & Nathan Rosenberg (ed.), Handbook of the Economics of Innovation, edition 1, volume 1, chapter 0, pages 539-574, Elsevier.
- Branstetter, Lee & Chatterjee, Chirantan & Higgins, Matthew J., 2022.
"Generic competition and the incentives for early-stage pharmaceutical innovation,"
Research Policy, Elsevier, vol. 51(10).
- Lee Branstetter & Chirantan Chatterjee & Matthew J. Higgins, 2014. "Generic Competition and the Incentives for Early-Stage Pharmaceutical Innovation," NBER Working Papers 20532, National Bureau of Economic Research, Inc.
- Grabowski, Henry & Vernon, John & DiMasi, Joseph, 2002.
"Returns on R&D for 1990s New Drug Introductions,"
Working Papers
02-21, Duke University, Department of Economics.
- Henry Grabowski & John Vernon & Joseph DiMasi, 2003. "Returns on R&D for 1990s New Drug Introductions," Levine's Working Paper Archive 618897000000000666, David K. Levine.
- Cardoso de Mendonca, Mario Jorge & Sachsida, Adolfo & Loureiro, Paulo R. A., 2003. "A study on the valuing of biodiversity: the case of three endangered species in Brazil," Ecological Economics, Elsevier, vol. 46(1), pages 9-18, August.
- DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
- Steven Casper;Hannah Kettler, 2000. "The Road to Sustainability in the UK and German Biotechnology Industries," Monograph 000466, Office of Health Economics.
- Schwartz, Eduardo S., 2002. "Patents and R& D as Real Options," University of California at Los Angeles, Anderson Graduate School of Management qt86b1n43k, Anderson Graduate School of Management, UCLA.
- Billette de Villemeur, Etienne & Versaevel, Bruno, 2019.
"One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry,"
Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
- Billette de Villemeur, Etienne & Versaevel, Bruno, 2017. "One Lab, Two Firms, Many Possibilities: on R&D outsourcing in the biopharmaceutical industry," MPRA Paper 76903, University Library of Munich, Germany.
- Etienne Billette de Villemeur & Bruno Versaevel, 2019. "One Lab, Two Firms, Many Possibilities: on R&D outsourcing in the biopharmaceutical industry," Post-Print hal-02107357, HAL.
- Bruno Versaevel, 2018. "One lab, two firms, many Possibilities: On R&D outsourcing in the biopharmaceutical industry," Post-Print halshs-01960435, HAL.
- Bruno Versaevel, 2018. "One lab, two firms, many Possibilities: On R&D outsourcing in the biopharmaceutical industry," Post-Print halshs-01960426, HAL.
- Samira Guennif, 2007. "Global harmonisation of intellectual property rights and local impact. Patent and access to medicines in developing countries under TRIPS and TRIPS plus provisions [Harmonisation globale des systèm," Post-Print hal-01345869, HAL.
- Scherer, F. M., 2007. "Pharmaceutical Innovation," Working Paper Series rwp07-004, Harvard University, John F. Kennedy School of Government.
- Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
- Mark Pauly & Kyle Myers, 2016. "A Ricardian-Demand Explanation for Changing Pharmaceutical R&D Productivity," NBER Working Papers 22720, National Bureau of Economic Research, Inc.
- Scott, Anthony & Hall, Jane, 1995. "Evaluating the effects of GP remuneration: problems and prospects," Health Policy, Elsevier, vol. 31(3), pages 183-195, March.
- Yin, Nina, 2023. "Pharmaceuticals, incremental innovation and market exclusivity," International Journal of Industrial Organization, Elsevier, vol. 87(C).
- Ming Ding & Jehoshua Eliashberg, 2002. "Structuring the New Product Development Pipeline," Management Science, INFORMS, vol. 48(3), pages 343-363, March.
- Daron Acemoglu & Joshua Linn, 2004.
"Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry,"
The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 119(3), pages 1049-1090.
- Daron Acemoglu & Joshua Linn, 2003. "Market Size in Innovation: Theory and Evidence From the Pharmaceutical Industry," NBER Working Papers 10038, National Bureau of Economic Research, Inc.
- Daron Acemoglu & Joshua Linn, 2004. "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry," Levine's Working Paper Archive 228400000000000002, David K. Levine.
- Patricia M. Danzon & Allison Percy, 1999. "The Effects of Price Regulation on Productivity in Pharmaceuticals," NBER Chapters, in: International and Interarea Comparisons of Income, Output, and Prices, pages 371-418, National Bureau of Economic Research, Inc.
- Natasha Palmer & Anne Mills, 2003. "Classical versus relational approaches to understanding controls on a contract with independent GPs in South Africa," Health Economics, John Wiley & Sons, Ltd., vol. 12(12), pages 1005-1020, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:chy:respap:113chedp. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Gill Forder (email available below). General contact details of provider: https://edirc.repec.org/data/chyoruk.html .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.